The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical significances of pAkt and pErk1/2 in patients with early-stage breast cancer treated with anthracycline-based adjuvant chemotherapy.
Y. Teng
No relevant relationships to disclose
W. Liu
No relevant relationships to disclose
X. Qu
No relevant relationships to disclose
L. Zhou
No relevant relationships to disclose
L. Zhang
No relevant relationships to disclose
J. Zhang
No relevant relationships to disclose
M. Zhao
No relevant relationships to disclose
P. Yu
No relevant relationships to disclose
B. Jin
No relevant relationships to disclose
Y. Luo
No relevant relationships to disclose
J. Shi
No relevant relationships to disclose
Y. Liu
No relevant relationships to disclose